• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Clostridium Botulinum Infections - Pipeline Review, H2 2012 Product Image

Clostridium Botulinum Infections - Pipeline Review, H2 2012

  • ID: 2233832
  • August 2012
  • 39 pages
  • Global Markets Direct

Clostridium Botulinum Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Clostridium Botulinum Infections - Pipeline Review, H2 2012', provides an overview of the Clostridium Botulinum Infections therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Botulinum Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Botulinum Infections. 'Clostridium Botulinum Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Clostridium Botulinum Infections.
- READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Clostridium Botulinum Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Clostridium Botulinum Infections 7
Clostridium Botulinum Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Clostridium Botulinum Infections Therapeutics – Products under Development by Companies 14
Companies Involved in Clostridium Botulinum Infections Therapeutics Development 15
Emergent BioSolutions Inc. 15
Cangene Corporation 16
XOMA Ltd. 17
Morphotek, Inc. 18
AlphaVax, Inc. 19
DynPort Vaccine Company LLC 20
Molecular Targeting Technologies, Inc. 21
Clostridium Botulinum Infections – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
MORAb-047 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Recombinant Botulinum Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Botulinum Toxin Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
XOMA 3AB - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Botulism Antitoxin Heptavalent - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
rBV A/B - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Botulinum Toxin Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Clostridium Botulinum Infections Therapeutics – Drug Profile Updates 36
Clostridium Botulinum Infections – Product Development Milestones 37
Featured News & Press Releases 37
May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Clostridium Botulinum Infections, H2 2012 7
Products under Development for Clostridium Botulinum Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Emergent BioSolutions Inc., H2 2012 15
Cangene Corporation, H2 2012 16
XOMA Ltd., H2 2012 17
Morphotek, Inc., H2 2012 18
AlphaVax, Inc., H2 2012 19
DynPort Vaccine Company LLC, H2 2012 20
Molecular Targeting Technologies, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Clostridium Botulinum Infections Therapeutics – Drug Profile Updates 36

List of Figures
Number of Products under Development for Clostridium Botulinum Infections, H2 2012 7
Products under Development for Clostridium Botulinum Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos